In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes program. This program took a multifaceted approach to providing key funding to diabetes researchers to advance a broad spectrum of research programs on all aspects of understanding, managing, and treating diabetes. Here, the personal perspective of a 2019 Pathway Accelerator awardee is offered, describing a research program seeking to advance a materials-centered approach to engineering glucose-responsive devices and new delivery tools for better therapeutic outcomes in treating diabetes. This is offered alongside a personal reflection on 5 years of support from the ADA Pathway Program.
Five years of support from the ADA Pathway to Stop Diabetes program has resulted in significant progress from a research program on glucose-responsive therapeutics.
New chemistry for more sensitive and specific glucose binding has enabled improvements in materials and formulations for insulin delivery.
A new approach to glucose-stabilized materials has enabled materials and formulations for the delivery of glucagon.
